{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:50:11Z","timestamp":1792799411252,"version":"4.5.0"},"reference-count":171,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-006658 639"],"award-info":[{"award-number":["INV-006658 639"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Malaria remains a major global health burden, with an estimated 282 million cases and 610,000 deaths reported in 2024, disproportionately affecting children under five years of age and pregnant women in sub-Saharan Africa. Although antimalarial drugs are highly effective at clearing infections, their reliance on timely diagnosis and treatment limits their scalability as a population-wide control strategy. Vaccines therefore represent a critical tool for reducing malaria-associated morbidity and mortality, as well as interrupting parasite transmission, by inducing durable protective immunity. However, the complex lifecycle of Plasmodium parasites poses significant challenges for vaccine development, including the identification of protective antigens and optimal vaccine formulations. In this review, we summarize current vaccine strategies and discuss their key limitations. We also highlight emerging opportunities for possible avenues for future research and development.<\/jats:p>","DOI":"10.3390\/vaccines14030277","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T09:48:42Z","timestamp":1774259322000},"page":"277","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8092-1964","authenticated-orcid":false,"given":"Gulbuse","family":"Turan","sequence":"first","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxence J.","family":"Boggio","sequence":"additional","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-900X","authenticated-orcid":false,"given":"Ahmad Syibli","family":"Othman","sequence":"additional","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK"},{"name":"School of Biomedical Sciences, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Kuala Nerus 21300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-092X","authenticated-orcid":false,"given":"Victory","family":"Nnaemeka","sequence":"additional","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9629","authenticated-orcid":false,"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-7339","authenticated-orcid":false,"given":"Ahmed M.","family":"Salman","sequence":"additional","affiliation":[{"name":"Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"ref_1","unstructured":"WHO (2024). World Malaria Report, WHO."},{"key":"ref_2","unstructured":"WHO (2025). World Malaria Report, WHO."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cell.2016.07.055","article-title":"Malaria: Biology and disease","volume":"167","author":"Cowman","year":"2016","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.6.1.9677","article-title":"From the circumsporozoite protein to the RTS,S\/AS candidate vaccine","volume":"6","author":"Cohen","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"RTS, S Clinical Trials Partnership (2015). Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet, 386, 31\u201345.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"RTS, S Clinical Trials Partnership (2011). First Results of Phase 3 Trial of RTS,S\/AS01 Malaria Vaccine in African Children. N. Engl. J. Med., 365, 1863\u20131875.","DOI":"10.1056\/NEJMoa1102287"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1126\/science.adl5521","article-title":"First malaria vaccine slashes early childhood mortality","volume":"382","author":"Wadman","year":"2023","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS,S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: Secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41541-025-01167-0","article-title":"Role of malaria exposure and off-target responses on RTS,S\/AS02A vaccine immunogenicity and protection in Mozambican children","volume":"10","author":"Fuentes","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix\u2122): An overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ansong, D., Asante, K.P., Vekemans, J., Owusu, S.K., Owusu, R., Brobby, N.A., Dosoo, D., Osei-Akoto, A., Osei-Kwakye, K., and Asafo-Adjei, E. (2011). T cell responses to the RTS,S\/AS01E and RTS,S\/AS02D malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018891"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Moncunill, G., De Rosa, S.C., Ayestaran, A., Nhabomba, A.J., Mpina, M., Cohen, K.W., Jairoce, C., Rutishauser, T., Campo, J.J., and Harezlak, J. (2017). RTS,S\/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01008"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.vaccine.2023.01.043","article-title":"Cost of introducing and delivering RTS,S\/AS01 malaria vaccine within the malaria vaccine implementation program","volume":"41","author":"Baral","year":"2023","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kibwana, E., Bundi, C., Kimani, D., Nyamako, L., Keter, K., Mutiso, A., Ogwang, R., Bellamy, D., Rapi, K., and Bajer, A. (2025). R21\/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: Insights from a phase IIb controlled human malaria infection trial. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1620365"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: A multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: A randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100867","DOI":"10.1016\/S2666-5247(24)00083-1","article-title":"R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18\u201345 years: An open-label, partially blinded, phase 1\u20132a controlled human malaria infection study","volume":"6","author":"Venkatraman","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","article-title":"The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: A mathematical modelling study","volume":"24","author":"Schmit","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: A randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","article-title":"A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1","volume":"12","author":"Roestenberg","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Illingworth, J.J., Alanine, D.G., Brown, R., Marshall, J.M., Bartlett, H.E., Silk, S.E., Labb\u00e9, G.M., Quinkert, D., Cho, J.S., and Wendler, J.P. (2019). Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01254"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S1473-3099(24)00312-8","article-title":"Blood-stage malaria vaccine candidate RH5.1\/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial","volume":"24","author":"Silk","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","article-title":"Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination","volume":"2","author":"Minassian","year":"2021","journal-title":"Med"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e96381","DOI":"10.1172\/jci.insight.96381","article-title":"Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.pt.2024.09.001","article-title":"RH5: Rationally-designed malaria vaccine antigen improving efficacy","volume":"40","author":"Takashima","year":"2024","journal-title":"Trends Parasitol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101654","DOI":"10.1016\/j.xcrm.2024.101654","article-title":"Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies","volume":"5","author":"King","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2ra5","DOI":"10.1126\/scitranslmed.3000257","article-title":"Extreme polymorphism in a vaccine antigen and risk of clinical malaria: Implications for vaccine development","volume":"1","author":"Takala","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"985651","DOI":"10.1155\/2015\/985651","article-title":"Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso","volume":"2015","author":"Soulama","year":"2015","journal-title":"J. Parasitol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cai, J., Chen, S., Zhu, F., Lu, X., Liu, T., and Xu, W. (2021). Whole-Killed Blood-Stage Vaccine: Is It Worthwhile to Further Develop It to Control Malaria?. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.670775"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Spring, M.D., Cummings, J.F., Ockenhouse, C.F., Dutta, S., Reidler, R., Angov, E., Bergmann-Leitner, E., Stewart, V.A., Bittner, S., and Juompan, L. (2009). Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005254"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1590\/s1678-9946202264023","article-title":"Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: A brief review","volume":"64","author":"Alves","year":"2022","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e12386","DOI":"10.1111\/pim.12386","article-title":"A whole-killed, blood-stage lysate vaccine protects against the malaria liver stage","volume":"39","author":"Lu","year":"2017","journal-title":"Parasite Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12936-021-03723-0","article-title":"Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone","volume":"20","author":"McCoy","year":"2021","journal-title":"Malar. J."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Brod, F., Miura, K., Taylor, I., Li, Y., Marini, A., Salman, A.M., Spencer, A.J., Long, C.A., and Biswas, S. (2018). Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02780"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1038\/srep18848","article-title":"Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","article-title":"Malaria vaccines: A new era of prevention and control","volume":"22","author":"Duffy","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1473-3099(19)30739-X","article-title":"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: A first-in-human, randomised, double-blind, placebo-controlled study","volume":"20","author":"Sirima","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciy1140","article-title":"First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria","volume":"69","author":"Mordmuller","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ma, R., Salinas, N.D., Orr-Gonzalez, S., Richardson, B., Ouahes, T., Torano, H., Jenkins, B.J., Dickey, T.H., Neal, J., and Duan, J. (2024). Structure-guided design of VAR2CSA-based immunogens and a cocktail strategy for a placental malaria vaccine. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1011879"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Misal, S.A., Renn, J.P., Morrison, R.D., Cowles, M.V., Mahamar, A., Attaher, O., Dicko, A., Duffy, P.E., and Fried, M. (2025). Identification of Plasmodium falciparum VAR2CSA peptides differentially recognized by IgG of multigravidae through epitope excision. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1704346"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","article-title":"Malaria vaccines since 2000: Progress, priorities, products","volume":"5","author":"Duffy","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Goh, Y.S., McGuire, D., and R\u00e9nia, L. (2019). Vaccination With Sporozoites: Models and Correlates of Protection. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01227"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1038\/s41598-018-21369-y","article-title":"Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model","volume":"8","author":"Yoshida","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4161\/hv.24941","article-title":"Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection","volume":"9","author":"Tamminga","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/j.amepre.2015.09.011","article-title":"The March Toward Malaria Vaccines","volume":"49","author":"Hoffman","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tariq, H., Batool, S., Asif, S., Ali, M., and Abbasi, B.H. (2021). Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.790121"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Skwarczynski, M., Chandrudu, S., Rigau-Planella, B., Islam, M.T., Cheong, Y.S., Liu, G., Wang, X., Toth, I., and Hussein, W.M. (2020). Progress in the Development of Subunit Vaccines against Malaria. Vaccines, 8.","DOI":"10.3390\/vaccines8030373"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/328257a0","article-title":"Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites","volume":"328","author":"Herrington","year":"1987","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"978","DOI":"10.15585\/mmwr.mm7343a4","article-title":"Routine Vaccination Coverage\u2014Worldwide, 2023","volume":"73","author":"Jones","year":"2024","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites","volume":"185","author":"Hoffman","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1073\/pnas.1220360110","article-title":"Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity","volume":"110","author":"Bijker","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1056\/NEJMoa2313892","article-title":"Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite","volume":"391","author":"Lamers","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/s44321-024-00131-0","article-title":"Whole-sporozoite malaria vaccines: Where we are, where we are going","volume":"16","author":"Moita","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1016\/j.vaccine.2015.09.095","article-title":"Novel approaches to whole sporozoite vaccination against malaria","volume":"33","author":"Bijker","year":"2015","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"112589","DOI":"10.1016\/j.isci.2025.112589","article-title":"Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans","volume":"28","author":"Colstrup","year":"2025","journal-title":"iScience"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.4161\/21645515.2014.972764","article-title":"Live attenuated pre-erythrocytic malaria vaccines","volume":"10","author":"Keitany","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/s41467-025-58963-4","article-title":"Recent perspectives in clinical development of malaria vaccines","volume":"16","author":"Feehan","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_65","first-page":"29","article-title":"Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions","volume":"17","author":"Sallam","year":"2025","journal-title":"Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Covarrubias, C.E., Rivera, T.A., Soto, C.A., Deeks, T., and Kalergis, A.M. (2022). Current GMP standards for the production of vaccines and antibodies: An overview. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1021905"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41541-018-0071-7","article-title":"Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells","volume":"3","author":"Jin","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_68","unstructured":"Orenstein, W.A., Offit, P.A., Edwards, K.M., and Plotkin, S.A. (2018). Plotkin\u2019s Vaccines, Elsevier."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","article-title":"Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults","volume":"4","author":"Silk","year":"2023","journal-title":"Med"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"103585","DOI":"10.1016\/j.eclinm.2025.103585","article-title":"Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: A randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial","volume":"89","author":"Kahatano","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wu, Y., Ellis, R.D., Shaffer, D., Fontes, E., Malkin, E.M., Mahanty, S., Fay, M.P., Narum, D., Rausch, K., and Miles, A.P. (2008). Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002636"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Talaat, K.R., Ellis, R.D., Hurd, J., Hentrich, A., Gabriel, E., Hynes, N.A., Rausch, K.M., Zhu, D., Muratova, O., and Herrera, R. (2016). Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel\u00ae, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Na\u00efve Adults. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163144"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1473-3099(23)00276-1","article-title":"Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial","volume":"23","author":"Sagara","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like particle vaccines: Immunology and formulation for clinical translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"He, J., Yu, L., Lin, X., Liu, X., Zhang, Y., Yang, F., and Deng, W. (2022). Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds. Viruses, 14.","DOI":"10.3390\/v14091905"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Khudyakov, Y., and Pumpens, P. (2016). Viral Nanotechnology, CRC Press.","DOI":"10.1201\/b18596"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mohsen, M.O., Gomes, A.C., Vogel, M., and Bachmann, M.F. (2018). Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines, 6.","DOI":"10.3390\/vaccines6030037"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4155\/tde.14.74","article-title":"Antigen delivery by virus-like particles for immunotherapeutic vaccination","volume":"5","author":"Donaldson","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.4049\/jimmunol.172.10.6129","article-title":"Loading of MHC class I and II presentation pathways by exogenous antigens: A quantitative in vivo comparison","volume":"172","author":"Storni","year":"2004","journal-title":"J. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s44222-023-00044-6","article-title":"Plant-based biopharmaceutical engineering","volume":"1","author":"Eidenberger","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41541-019-0111-y","article-title":"Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages","volume":"4","author":"Makarkov","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gupta, R., Arora, K., Roy, S.S., Joseph, A., Rastogi, R., Arora, N.M., and Kundu, P.K. (2023). Platforms, advances, and technical challenges in virus-like particles-based vaccines. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1123805"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/bit.21716","article-title":"Escherichia coli-based cell-free synthesis of virus-like particles","volume":"100","author":"Bundy","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against Plasmodium falciparum Malaria","volume":"336","author":"Stoute","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay, E., Camacho, C.L., Hill, A.V.S., and Salman, A.M. (2025). Subcutaneous administration of the malaria R21\/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1675780"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/jamapediatrics.2025.3568","article-title":"Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction","volume":"179","author":"DeSieghardt","year":"2025","journal-title":"JAMA Pediatr."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zeng, Y., Moscicki, A.B., Sahasrabuddhe, V.V., Garcia, F., Woo, H., Hsu, C.H., Szabo, E., Dimond, E., Vanzzini, S., and Mondragon, A. (2019). A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9\u201311\u2009year-old girls and boys\u2014Clinical protocol. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5444-4"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B Vaccine","volume":"303","author":"Szmuness","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)61030-6","article-title":"Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial","volume":"376","author":"Zhu","year":"2010","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"101000","DOI":"10.1016\/j.lanmic.2024.101000","article-title":"Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: An open-label, parallel-group, age-matched, sex-matched, phase 2 randomised controlled study","volume":"6","author":"Hamer","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1021\/nn201397z","article-title":"Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles","volume":"5","author":"Ashley","year":"2011","journal-title":"ACS Nano"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1021\/acsanm.8b00480","article-title":"Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo","volume":"1","author":"Suffian","year":"2018","journal-title":"ACS Appl. Nano Mater."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e0103021","DOI":"10.1128\/JVI.01030-21","article-title":"Paramyxovirus-Like Particles as Protein Delivery Vehicles","volume":"95","author":"Panthi","year":"2021","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-018-0084-2","article-title":"Safety and efficacy of novel malaria vaccine regimens of RTS,S\/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP","volume":"3","author":"Rampling","year":"2018","journal-title":"npj Vaccines"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e0072820","DOI":"10.1128\/IAI.00728-20","article-title":"Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from Plasmodium Infection in a Murine Model","volume":"89","author":"Reeder","year":"2021","journal-title":"Infect. Immun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1089\/10430340260201644","article-title":"Safety, Tolerability, and Lack of Antibody Responses After Administration of a PfCSP DNA Malaria Vaccine via Needle or Needle-Free Jet Injection, and Comparison of Intramuscular and Combination Intramuscular\/Intradermal Routes","volume":"13","author":"Epstein","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4161\/hv.22129","article-title":"Clinical trial in healthy malaria-na\u00efve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite\/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA","volume":"8","author":"Richie","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Chuang, I., Sedegah, M., Cicatelli, S., Spring, M., Polhemus, M., Tamminga, C., Patterson, N., Guerrero, M., Bennett, J.W., and McGrath, S. (2013). DNA Prime\/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055571"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-023-00783-y","article-title":"mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response","volume":"9","author":"Scaria","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum","volume":"7","author":"Hayashi","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-025-01089-x","article-title":"iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA","volume":"10","author":"Yanik","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Rappuoli","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eabb1025","DOI":"10.1126\/sciimmunol.abb1025","article-title":"3M-052, a synthetic TLR-7\/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates","volume":"5","author":"Kasturi","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"eadi8039","DOI":"10.1126\/sciimmunol.adi8039","article-title":"AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans","volume":"9","author":"Grigoryan","year":"2024","journal-title":"Sci. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"eado5937","DOI":"10.1126\/sciimmunol.ado5937","article-title":"Linking vaccine adjuvant mechanisms of action to function","volume":"10","author":"Chapman","year":"2025","journal-title":"Sci. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"B14","DOI":"10.1016\/j.vaccine.2015.01.088","article-title":"New generation adjuvants\u2014From empiricism to rational design","volume":"33","author":"Fox","year":"2015","journal-title":"Vaccine"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1096\/fj.11-184556","article-title":"Antigen depot is not required for alum adjuvanticity","volume":"26","author":"Hutchison","year":"2012","journal-title":"Faseb J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Awate, S., Babiuk, L.A., and Mutwiri, G. (2013). Mechanisms of action of adjuvants. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00114"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Reimer, J.M., Karlsson, K.H., L\u00f6vgren-Bengtsson, K., Magnusson, S.E., Fuentes, A., and Stertman, L. (2012). Matrix-M\u2122 adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041451"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Carnrot, C., Carow, B., Palm, A.-K.E., Akpinar, E., Helgesson, P.-H., Osterman, I.L., Bringeland, E., Foreman, B., Patel, N., and Bankefors, J. (2023). Biodistribution of the saponin-based adjuvant Matrix-M\u2122 following intramuscular injection in mice. Front. Drug Deliv., 3.","DOI":"10.3389\/fddev.2023.1279710"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1473-3099(21)00192-4","article-title":"Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: A phase 3 randomised controlled trial","volume":"22","author":"Shinde","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiz518","article-title":"Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults","volume":"222","author":"Fries","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12936-022-04169-8","article-title":"Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial","volume":"21","author":"Nouatin","year":"2022","journal-title":"Malar. J."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Ou\u00e9draogo, A., Bougouma, E.C., Palacpac, N.M.Q., Houard, S., Nebie, I., Sawadogo, J., Berges, G.D., Soulama, I., Diarra, A., and Hien, D. (2023). Safety and immunogenicity of BK-SE36\/CpG malaria vaccine in healthy Burkinabe adults and children: A phase 1b randomised, controlled, double-blinded, age de-escalation trial. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1267372"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4269\/ajtmh.2011.09-0516","article-title":"Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51","volume":"84","author":"Herrera","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiae062","article-title":"Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge","volume":"229","author":"Berry","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"eadn6605","DOI":"10.1126\/scitranslmed.adn6605","article-title":"A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates","volume":"16","author":"Arunachalam","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e0079824","DOI":"10.1128\/msphere.00798-24","article-title":"Virus-like particle-based vaccines targeting the Anopheles mosquito salivary protein TRIO","volume":"10","author":"Francian","year":"2025","journal-title":"mSphere"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41541-025-01241-7","article-title":"Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria","volume":"10","author":"Nepal","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e20241908","DOI":"10.1084\/jem.20241908","article-title":"Repertoire, function, and structure of serological antibodies induced by the R21\/Matrix-M malaria vaccine","volume":"222","author":"McDaniel","year":"2025","journal-title":"J. Exp. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e17454","DOI":"10.15252\/emmm.202317454","article-title":"Molecular and functional properties of human Plasmodium falciparum CSP C-terminus antibodies","volume":"15","author":"Oludada","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Fisher, C.R., Sutton, H.J., Kaczmarski, J.A., McNamara, H.A., Clifton, B., Mitchell, J., Cai, Y., Dups, J.N., D\u2019Arcy, N.J., and Singh, M. (2017). T-dependent B cell responses to Plasmodium induce antibodies that form a high-avidity multivalent complex with the circumsporozoite protein. PLoS Pathog., 13.","DOI":"10.1101\/108746"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e24067","DOI":"10.1002\/pep2.24067","article-title":"Disordered epitopes as peptide vaccines","volume":"110","author":"MacRaild","year":"2018","journal-title":"Pept. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"eaap8029","DOI":"10.1126\/sciimmunol.aap8029","article-title":"Clonal selection drives protective memory B cell responses in controlled human malaria infection","volume":"3","author":"Murugan","year":"2018","journal-title":"Sci. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.291.5501.141","article-title":"Migration of Plasmodium sporozoites through cells before infection","volume":"291","author":"Mota","year":"2001","journal-title":"Science"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.pt.2024.10.017","article-title":"The Plasmodium circumsporozoite protein","volume":"40","author":"Singer","year":"2024","journal-title":"Trends Parasitol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.20040989","article-title":"The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion","volume":"201","author":"Coppi","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1473-3099(22)00793-9","article-title":"Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): A phase 1, adaptive trial","volume":"23","author":"Lyke","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","article-title":"Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria","volume":"390","author":"Kayentao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-023-02659-z","article-title":"A candidate antibody drug for prevention of malaria","volume":"30","author":"Williams","year":"2024","journal-title":"Nat. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41541-024-01006-8","article-title":"Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development","volume":"9","author":"Krenger","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1038\/s41467-023-40151-x","article-title":"Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection","volume":"14","author":"Martin","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.mib.2017.12.001","article-title":"Tissue-specific cellular immune responses to malaria pre-erythrocytic stages","volume":"40","author":"Silvie","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Miyawaki, A., Iizuka, Y., Sugino, H., and Watanabe, Y. (2019). IL-11 prevents IFN-\u03b3-induced hepatocyte death through selective downregulation of IFN-\u03b3\/STAT1 signaling and ROS scavenging. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211123"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2613.2001.00207.x","article-title":"The effect of IFN\u03b3 on the hepatocyte: Cell cycle and apoptosis","volume":"82","author":"Tura","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Gustifante, B.N., Khairani, S., Fauziah, N., Riswari, S.F., and Berbudi, A. (2025). Targeting T-Cell Activation for Malaria Immunotherapy: Scoping Review. Pathogens, 14.","DOI":"10.3390\/pathogens14010071"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3201\/eid1509.090471","article-title":"Cross-reactive Antibodies against avian influenza virus A (H5N1)","volume":"15","author":"Pichyangkul","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Weiss, W.R., and Jiang, C.G. (2012). Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031247"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Ganeshan, H., Huang, J., Belmonte, M., Belmonte, A., Inoue, S., Velasco, R., Maiolatesi, S., Limbach, K., Patterson, N., and Sklar, M.J. (2025). Human responses to the DNA prime\/chimpanzee adenovirus (ChAd63) boost vaccine identify CSP, AMA1 and TRAP MHC Class I-restricted epitopes. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0318098"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Heide, J., Vaughan, K.C., Sette, A., Jacobs, T., and Schulze zur Wiesch, J. (2019). Comprehensive Review of Human Plasmodium falciparum-Specific CD8+ T Cell Epitopes. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00397"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/s41591-025-03739-y","article-title":"Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial","volume":"31","author":"Skinner","year":"2025","journal-title":"Nat. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1475-2875-12-185","article-title":"Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)","volume":"12","author":"Sedegah","year":"2013","journal-title":"Malar. J."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"104985","DOI":"10.1016\/j.meegid.2021.104985","article-title":"In silico analysis and prediction of immunogenic epitopes for pre-erythrocytic proteins of the deadly Plasmodium falciparum","volume":"93","author":"Asghari","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"eadr8382","DOI":"10.1126\/science.adr8382","article-title":"Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans","volume":"389","author":"Willis","year":"2025","journal-title":"Science"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"106998","DOI":"10.1016\/j.mimet.2024.106998","article-title":"Leveraging artificial intelligence in vaccine development: A narrative review","volume":"224","author":"Olawade","year":"2024","journal-title":"J. Microbiol. Methods"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40794-025-00248-1","article-title":"Current update on malaria in pregnancy: A systematic review","volume":"11","author":"Minwuyelet","year":"2025","journal-title":"Trop. Dis. Travel. Med. Vaccines"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"eaat6176","DOI":"10.1126\/scitranslmed.aat6176","article-title":"In utero priming of highly functional effector T cell responses to human malaria","volume":"10","author":"Odorizzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1473-3099(24)00360-8","article-title":"Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"24","author":"Diawara","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e00021-25","DOI":"10.1128\/iai.00021-25","article-title":"Multi-system dysregulation in placental malaria contributes to adverse perinatal outcomes in mice","volume":"93","author":"Ekregbesi","year":"2025","journal-title":"Infect. Immun."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12936-024-04960-9","article-title":"Plasmodium falciparum alters the trophoblastic barrier and stroma villi organization of human placental villi explants","volume":"23","author":"Ramirez","year":"2024","journal-title":"Malar. J."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Atcheson, E., Bauza, K., Salman, A.M., Alves, E., Blight, J., Viveros-Sandoval, M.E., Janse, C.J., Khan, S.M., Hill, A.V.S., and Reyes-Sandoval, A. (2018). Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. Infect. Immun., 86.","DOI":"10.1128\/IAI.00114-18"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/277\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:57:52Z","timestamp":1774331872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":171,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["vaccines14030277"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14030277","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}